Biosign is a Healthcare Information Technology company. Our products include intelligent software platforms delivering noninvasive gathering, analysis and reporting of critical vital signs and biological parameters. The company is publicly listed on the TSX - Venture Exchange (TSX-V:BIO). We have been a listed company since July 14, 2006. Our auditors are Collins Barrow LLP and our corporate filings are available on SEDAR.

April 8
Biosign Closes Acquisition of IBL Internet Business Logic Inc.

Biosign Technologies Inc. is pleased to announce that on March 31, 2014, the Company closed the acquisition of IBL Internet Business Logic Inc. The execution of the share purchase agreement was previously announced on December 31, 2013.

March 25
Biosign positions itself for growth: Strengthens the Board, secures debt financing & looks to acquire additional software assets

Capitalizing on Opportunities for Rapid Growth:

After extensive research, the Company has concluded that the primary unmet need in the markets we serve is the urgent requirement to connect those in need of care with service providers who deliver care using new cloud-based software solutions. For example, a typical clinic uses paper-based forms and labour intensive practices to schedule appointments, resulting in waste and inefficiency. At the same time, clients have no easy online access to information about the care they receive. Since our software is effective in streamlining the internal management of clinics, Biosign is in the unique position to connect customers to their healthcare providers in a convenient, seamless way.

The Company is pursuing two parallel paths to growth: we are creating innovative proprietary solutions that disrupt incumbent players and at the same time we are acquiring synergistic assets that increase speed-to-market and deliver profits. Biosign continues to execute both these strategies by improving our patent-pending Pulsewave® technology while simultaneously integrating QCARE & ClinicServer with additional assets into a unique and compelling platform.

Under this strategy Biosign is participating in the Qualcomm Tricorder XPRIZE competition, a $10 million innovation contest to develop a Star Trek-like software system to record all 5 vital signs and independently diagnose 15 separate diseases. A 2012 study by Parks Associates ("Digitally Fit: Healthy Living and Connected Devices") predicts that more than 32 million US consumers will actively track their health & fitness online by 2016, up from about 15 million in 2011 (~100% growth). Revenue from online / mobile wellness service adoption will increase from $337 million in 2011 to more than $2.4 billion by 2016 (~700% growth), according to the study.

February 6
Biosign enjoys success at Arab Health 2014

Biosign Technologies Inc. is pleased to announce the execution of a Memorandum of Understanding with Novosante Healthcare, a division of Sharjah UAE based Gulf Holdings LLC.

February 5
Biosign supports Heart & Stroke Foundation during Heart Month

Biosign is pleased to announce that Biosign will once again support the Canadian Heart & Stroke Foundation during "Heart Month".

January 8
Biosign acquires 100% of QLINE Solutions Inc.

Biosign Technologies Inc. is pleased to announce the execution of a Share Purchase Agreement (the "SPA") under which it has agreed to acquire 100% of the issued and outstanding shares of Peterborough, Ontario based QLINE Solutions Inc. ("QLINE"), a privately held Ontario corporation founded in 1985, QLINE produces the QCARE Integrated Product Suite, which is a comprehensive software platform, used primarily to manage medium-to-large companies in the Home Care and Extended Care industries.

January 6
Biosign appoints new Chief Financial Officer and schedules Investor Conference Call

Biosign Technologies Inc. is pleased to announce the appointment of Mr. Mario Laflamme, CA, CPA as Chief Financial Officer, to replace Mr. William Randolph (Randy) Polley, CA who will remain with the Company as a senior business development executive.

Biosign is pleased to announce an Investor Conference Call, scheduled for Thursday, January 9th, 2014 at 11:00 AM Eastern Daylight Time.  During this call, Biosign CEO Robert Kaul will read a prepared statement commenting on recent news releases and providing additional discussion on the Company's business plan.

To participate in the call, please use the following login credentials:

Dial-In Number: Local: (718) 514-2085, Toll Free: 1-877-394-5901 
No PIN number is required. Participants can dial Star 1 (*1) to ask a question during the call - a live operator will be moderating.


December 31
Biosign acquires IBL Internet Business Logic Inc.

Biosign Technologies Inc. is pleased to announce the execution of a Share Purchase Agreement (the "SPA") under which it has agreed to acquire 100% of the issued and outstanding shares of Saint John NB based IBL Internet Business Logic ("IBL"), a practice management software developer and creator of ClinicServer® and PencilThat™ software platforms.

December 27
Biosign announces combined $6.0 million software and service sale

Biosign Technologies Inc. is pleased to announce that it has sold a $3.0 million software license to a large, UK publicly-traded healthcare services company with significant operations in EuropeAsia and North America, along with a separate $3 million software services agreement.

December 24
Biosign invests in HR infrastructure company

Biosign Technologies Inc. announced an investment in Vancouver, British Columbia-based Higher Bracket Online Media Inc, an innovative human resources consultancy.

December 23
Biosign and RJL Systems Announce Co-Marketing Agreement

The Company has appointed Michigan-based RJL Systems Inc as a non-exclusive agent for sales of Biosign Pulsewave®monitoring system within the United States. In a parallel agreement, Biosign has been appointed by RJL as a non-exclusive agent for their Quantum IV Body Impedance Analysis technology in the United States and Canada, and the parties have agreed to co-market their healthcare IT solutions.

The Company agreed to convert $157,720.25 owing to approximately 7 parties, one of whom is a related party as they are a director of the Company into common shares at a price of $0.05 per share. Subject to regulatory approval, 3,147,305 common shares shall be issued in full satisfaction of the Indebtedness, 30,225 shares are being issued to a director of the Company. The common shares will be subject to a regulatory hold period of 4 months and 1 day.

November 29
Biosign announces Annual General and Special Meeting

Biosign will hold its Annual General Meeting of Shareholders will be held at the Admiral Inn, 2161 N Sheridan Way, Mississauga, Ontario on February 6, 2014 at 11:00 a.m. (Toronto time).

Biosign has agreed to repatriate the exclusive reseller rights previously granted to ALQAEM International FZE ("ALQAEM"), ofSharjah, United Arab Emirates

November 25
Biosign to hold Investor Conference Call

Biosign is pleased to announce an Investor Conference Call, scheduled for Wednesday, November 27th, 2013 at 11:00 AM Eastern Daylight Time.

November 18
Biosign licenses award-winning applepeak source code

Biosign is pleased to announce the execution of a license agreement with Saint John NB based applepeak software to acquire a fully paid up, perpetual, royalty free, non-exclusive license to use and modify the source code for the "applepeak Wellness Record" software platform.

November 8
Biosign Investor Update

X-Prize Contestants Announced; Qline Acquisition Revised

Biosign has entered the Tricorder XPRIZE Competition under the team name "Cloud DX"

As a result of favourable discussions with the QLINE management team and greater visibility into QLINE's projected revenue and operations, the Company has entered into an amended term sheet pursuant to which it will increase the percentage of QLINE to be acquired from 51% to 72%. The total purchase will be satisfied with the previously agreed $630,000 in cash and by the issuance of 31,000,000 common shares of Biosign at an ascribed value of $0.05 per share.

November 6
Biosign Debuts Featuring Futuristic Health Monitor

Biosign Technologies Inc. will demonstrate itsPulsewave® MAX healthcare monitoring device when making its first appearance at MEDICA, the world’s largest annual medical trade fair, November 20-23 in Düsseldorf, Germany. Biosign has entered the Pulsewave MAX in the Qualcomm Tricorder X-Prize, a $10 million innovation contest to build a working device most resembling the all-seeing Tricorder® handheld monitor imagined in the television series Star Trek.

October 23
Investor Update

Biosign Technologies Appoints Two Investor Relations Firms,Investor Cubed and Frontier Merchant Capital Group.

Biosign closes private placement for $1,036,800.

September 23
Investor Update

Biosign Purchases Patient Portal Software Product

The Company has entered into an Asset Purchase Agreement with Saint John, NB based Business Health Matters Inc. ("BHM") pursuant to which the Company has purchased the source code to BHM's Employee Wellness software product (the "BHM Portal") for a purchase price of $113,000.00.

August 14
Biosign to Showcase Star Trek-like Health Monitor at Medica Debut

Biosign will bring two major innovations in patient monitoring when the Company exhibits for the first time at MEDICA, the globe’s largest annual medical trade fair. Regarded as the world stage for medical invention, MEDICA 2013 in Dusseldorf Germany, November 20-23 will attract over 4,000 exhibitors from more than 60 countries.

The first is our feature-rich, workflow-speeding “Healthanywhere™” integrated patient monitoring platform and the second is, perhaps more intriguingly to many, our “Pulsewave™ MAX”, a futuristic multi-sensor, cuff-and-monitor device that has been compared to the famous “Tricorder®” on Star Trek.

August 8
Biosign Adds New Board Director

The Company is pleased to announced the appointment of Dr. Michael Gross to the Company's Board of Directors.

Dr. Gross is a Professor of Orthopaedic surgery at Dalhousie University in Halifax, Nova Scotia and Medical Director of the regional tissue bank which is regulated by 6 different bodies. 

July 25
Biosign announces $180,000 clinical validation study

Biosign Technologies Inc. announced the completion of a Memorandum of Understanding with Health + Life Science New Brunswick Inc. to participate in the Biosign Critical Care Validation Project, an equal-stake private-public co-operative project between Biosign, HLSNB, theNew Brunswick Health Research Foundation and the University of New Brunswick, Saint John.

July 12
Biosign begins television advertising

The Company is pleased to announce that a new television advertising campaign will launch on Monday July 15th, 2013. Biosign will run television ads for the Pulsewave™ Health Monitor in multiple markets including St John, Fredericton & Moncton, NB as well as Toronto ON, on the Rogers TV Listings Channel.  A 30-second spot will highlight the most important features of the Pulsewave™ system, including the fact that Pulsewave™ is the only approved, over-the-counter system that allows the user to see their heart beat in real time on the computer screen.

July 11
Biosign enters into LOI with QLINE Solutions

Biosign Technologies Inc. announces that it has executed a Term Sheet pursuant to which Biosign will purchase a 51% interest in Peterborough ON-based software development company QLINE Solutions Inc. (QLINE), for a purchase price of $1.53 million.

July 5
Biosign Investor Conference Call scheduled

Biosign is pleased to announce an Investor Conference Call, scheduled for Monday, July 15th, 2013 at 11:00 AM Eastern Daylight Time. During this call, Biosign CEO Robert Kaul will read a prepared statement commenting on recent news releases and placing those releases into the context of the Company's business plan. Following this presentation, Mr. Kaul will answer a number of questions submitted in advance in writing, regarding the business of the Company.

Dial-In Number: 877-394-5901     Participant Code: 2169148

June 24
Biosign Begins Sales Effort In the United States

Biosign is pleased to announce sales of both Pulsewave Health Monitors and Healthanywhere patient monitoring software and services to US customers. Effective immediately, the US Medical Device Establishment listing for Biosign and the Medical Device Product listings for Pulsewave and Healthanywhere are active on the FDA website and are valid until 2013-12-31.

June 11
Biosign Investor Update

Biosign to begin Retail Sales of Pulsewave™

Biosign Technologies Inc. made the following statement:

Biosign is pleased to announce the launch of a new e-commerce initiative. For the first time, the general public may now purchase the Health Canada approved Pulsewave™ Monitor system directly from Biosign at

May 29
Biosign investor update

New Sales Agent / Value Added Reseller

Biosign has partnered with IBL-Internet Business Logic Inc ("ClinicServer"), a developer of Cloud-based clinical management software, based in Saint John New Brunswick to jointly integrate Biosign's Pulsewave™ health monitor technology and Healthanywhere™ telehealth monitoring platform into ClinicServer's "ClinicServer Flex™" clinical management software solution.  Both ClinicServer and Biosign will sell the resulting integrated package.  Based on the success of the Heart Friendly Dentist program, Biosign actively sought out a partner who could address the rapidly growing market for Allied Health practice optimization solutions. ClinicServer is a genuine pioneer and technology innovator within the Allied Health market.

March 18
Biosign Corporate Update

Biosign Technologies Inc. today announced the following:

Appointment of a new US Sales Agent, opening order of 100 Pulsewave™ devices:

Clear2there LLC, a leading provider of advanced video surveillance, smart-home, smart-business, communications, and machine-to-machine (M2M) solutions for service providers and enterprises, announced it has joined forces with Biosign to address the burgeoning market for smart healthcare and monitoring solutions.

March 15
Biosign Corporate Update

Biosign Technologies Inc. today announced the following:

Changes to the Board of Directors:

Biosign announces the resignation of directors Mr. Jason Meretsky and Senator Alfonse D'Amato, effective immediately. 

Biosign is pleased to announce the appointment of two new directors:

Dr. Sandeep (Sonny) Kohli and Mr. Dennis Rygwalski.

March 5
Biosign Announces Successful Heart Month Promotion

Biosign Technologies Inc. announced that during the month of February, 2013 in partnership with sales agent Dominion Medical, Biosign achieved 100% retention of the Heart Friendly™ Dentist customer accounts up for renewal during that month. As previously announced February 4th, 2013, Biosign will donate a percentage of the proceeds from each Heart Friendly™ Dentist enrollment during the month of February to the Heart & Stroke Foundation of Canada (the "Foundation").

March 1
Biosign Corporate Update

Restatement of the Engagement of Mr. Peter Hamilton: With respect to the previously announced appointment of Mr. Peter Hamilton to the position of Executive Vice President of Business Development of the Company on December 21, 2012, due to a revision in the Company's restructuring plan, Mr. Hamilton's relationship with the Company has been changed. Rosseau Consulting Inc., of which Mr. Hamilton is an employee, has been retained as a consultant to provide business development services to the Company. As part of such services, Mr. Hamilton will assist in the provision of such services with the title of Business Development Consultant. As a result, Mr. Hamilton is not an executive or employee of the Company and his relationship to Biosign is that of an independent consultant.

February 4
Biosign Investor Update

BIOSIGN APPOINTS SALES AGENT TO THE CANADIAN DENTAL MARKET. Dominion Medical Supply Inc ("Dominion"), a Dunville, ON-based specialty medical/dental sales agent, has been appointed to represent Biosign products to the Canadian dental market. 

BIOSIGN & DOMINION RE-LAUNCH "HEART FRIENDLY™ DENTIST" AND SUPPORT THE HEART & STROKE FOUNDATION DURING "HEART MONTH". In December 2012, Biosign acquired the assets of Bioanalytics Inc (see press release dated December 7th, 2012) including the brand name "Heart Friendly™" and associated marketing assets.

January 16
Biosign Technologies Announces Amended Closing On Private Placement

Biosign Technologies Inc. announced today an amendment to the scheduled closing applicable to an additional subscription of 6,000,000 units of the Company (the “Units”) at a purchase price of $0.05 per Unit, which formed part of its previously announced private placement financing (see news releases issued on November 29, 2012 and December 21, 2012).  Each Unit is comprised of one common share and one common share purchase warrant. Each common share purchase warrant is exercisable for a two-year period at $0.05 per share during the first 12 months and $0.10 per share in the second twelve months.

January 3
Biosign Technologies Completes Private Placement

Biosign Technologies Inc. is pleased to announce that on December 31st, 2012 it closed a private placement for 3,936,100 units of the Company (the "Units") at a purchase price of $0.05 per Unit, in addition to the previously announced placement (see news December 21, 2012) which forms part of its recently announced private placement financing (see news November 29, 2012) as approved by the Company's Board of Directors.  No director has an interest in the private placement. Each Unit is comprised of one common share and one common share purchase warrant. Each common share purchase warrant is exercisable for a 2-year period at $0.05 per share during the first twelve months and $0.10 per share in the second twelve months. The securities issued in connection with the Offering are subject to a four-month hold period from the issuance date in accordance with the policies of the TSXV and applicable securities laws.